Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | Synaptogenix, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
27.03. | Synaptogenix, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
20.12.24 | Synaptogenix, Inc. - 8-K, Current Report | - | SEC Filings | ||
SYNAPTOGENIX Aktie jetzt für 0€ handeln | |||||
26.06.24 | Synaptogenix, Inc.: Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis | 167 | PR Newswire | Collaborative study will evaluate drug's potential to improve synaptic health and cognitive function in MS patients
NEW YORK, June 26, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix"... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 94,20 | +0,69 % | BioNTech, Ceotronics, Deutz, Gerresheimer, Hensoldt, Renk - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
CUREVAC | 3,666 | -2,50 % | CureVac Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
AMGEN | 257,80 | +0,41 % | How Is Amgen's Stock Performance Compared to Other Pharmaceuticals Stocks? | ||
NOVAVAX | 6,305 | +0,11 % | Novavax Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
BIOGEN | 118,90 | +0,25 % | Biogen auf Goldman Sachs Konferenz: Strategische Änderungen und Pipeline-Fortschritte | ||
MAINZ BIOMED | 2,775 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed startet Machbarkeitsstudie zu Biomarker-Panel im Rahmen seines Projekts zur Behandlung von Bauchspeicheldrüsenkrebs | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed startet Machbarkeitsstudie zu Biomarker-Panel im Rahmen seines Projekts zur Behandlung von Bauchspeicheldrüsenkrebs... ► Artikel lesen | |
VIKING THERAPEUTICS | 25,705 | +0,74 % | Viking Therapeutics auf Jefferies-Konferenz: Vielversprechendes Abnehm-Medikament | ||
INTELLIA THERAPEUTICS | 7,484 | +1,00 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 9,680 | +0,41 % | BioCryst Pharmaceuticals, Inc.: BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries | RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland... ► Artikel lesen | |
TEMPUS AI | 60,06 | -1,09 % | Innovation Fuels Rally for Tempus AI: Should You Buy the Stock Today? | ||
SAREPTA THERAPEUTICS | 34,470 | +0,76 % | FDA Grants Platform Technology Status To Sarepta's RAAVrh74 Vector | WASHINGTON (dpa-AFX) - Sarepta Therapeutics (SRPT), Wednesday announced that the FDA has designated its rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 for limb-girdle... ► Artikel lesen | |
CARDIOL THERAPEUTICS | 1,268 | +0,32 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders | Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory... ► Artikel lesen | |
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,037 | +1,67 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - 8-K, Current Report | ||
EXELIXIS | 37,850 | +1,72 % | BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution | ||
VAXART | 0,534 | +55,36 % | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced that the Compensation Committee of the Board of Directors approved... ► Artikel lesen |